NCR3LG1 Antibody, HRP conjugated

Code CSB-PA737873LB01HU
Size US$166
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) NCR3LG1 Polyclonal antibody
Uniprot No.
Target Names
NCR3LG1
Alternative Names
NCR3LG1 antibody; B7H6 antibody; Natural cytotoxicity triggering receptor 3 ligand 1 antibody; B7 homolog 6 antibody; B7-H6 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Natural cytotoxicity triggering receptor 3 ligand 1 protein (25-262AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
HRP
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form
Liquid
Tested Applications
ELISA
Protocols
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Triggers NCR3-dependent natural killer cell activation.
Gene References into Functions
  1. B7-H6 was expressed in gliomas and correlated with glioma progression. Knockdown of B7-H6 inhibited glioma cell proliferation, colony formation, migration, and invasion via upregulation of E-cadherin and Bax, and downregulation of vimentin, N-cadherin, MMP-2, MMP-9 and survivin. PMID: 29679856
  2. these studies find that soluble B7H6 is constitutively expressed during pregnancy PMID: 29055565
  3. Data suggest that B7-H6 play an important role in the regulation of the biological behavior of glioma cells. PMID: 28415577
  4. Data indicate a sequence of events driven by tumour-derived prostaglandin D2 (PGD2) associated with engagement of the natural cytotoxicity triggering receptor 3 (NKp30)-B7H6 antigen (B7H6) pathway leading to significant group 2 innate lymphoid cells (ILC2s) activation and expansion. PMID: 28928446
  5. B7H6-derived peptides trigger TNF-alpha-dependent immunostimulatory activity of lymphocytic NK92-MI cells. PMID: 27216712
  6. Study confirms that B7-H6 is widely expressed in B-cell lymphomas and demonstrates its important role in the pathogenesis and chemosensitivity of lymphoma. PMID: 26891663
  7. our present data revealed that higher B7-H6 expression in ovarian cancer tissues was positively correlated with tumor metastasis and cancer progression PMID: 26464699
  8. NKp30-B7-H6 interaction is a novel cell contact mechanism that mediates activation of Group 2 innate lymphoid cells and identifies a potential target for the development of novel therapeutics for atopic dermatitis and other atopic diseases. PMID: 26582946
  9. study not only reveals the possibility that tumor therapeutics work as stress inducers to enhance tumor sensitivity to NK cell cytolysis but also suggests that B7-H6 could be a potential target for tumor therapy in the future PMID: 26472927
  10. Our results suggest that NKP30-B7-H6 interaction can aggravate hepatocyte damage, probably through up-regulation of IL-32 expression in hepatitis B virus-related acute-on-chronic liver failure PMID: 26241657
  11. the interaction between NKp30 and B7-H6 may contribute to the fate of neuroblastoma patients PMID: 25877893
  12. Study suggests that B7-H6 has a limited value as a prognostic marker in non-small cell lung cancer patients. PMID: 25400778
  13. this study identified ectodomain shedding of B7-H6 by the metalloproteases "a disintegrin and metalloproteases" (ADAM)-10 and ADAM-17 from the cell surface of tumor cells as a crucial mechanism of expression regulation of B7-H6. PMID: 24780758
  14. B7-H6-positive carcinomas were significantly associated with a higher differentiation. PMID: 24242703
  15. Allogeneic and xenogeneic anti-tumor effect of callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction. PMID: 25001651
  16. Data indicate that the ectodomain of NKp30 forms functional homo-oligomers that mediate high affinity binding to its corresponding cellular ligand B7-H6. PMID: 24275655
  17. These findings reveal that B7-H6 is not only implicated in tumor immunosurveillance but also participates in the inflammatory response in infectious conditions. PMID: 23687088
  18. B7-H6:7D8 represents the first Ab-based molecule stimulating NKp30-mediated NK cell cytotoxicity for therapeutic purposes PMID: 23066150
  19. The NKp30-B7-H6 structure revealed that this NK cell activating complex is distinct from the CTLA4-B7 and PD-1-PD-L T cell inhibitory complexes in both overall organization and detailed atomic interactions that mediate binding and specificity. PMID: 21422170
  20. DKFZp686O24166 was designated the gene B7-H6; identification as a tumor cell surface molecule that binds NKp30, a receptor which triggers antitumor NK cell cytotoxicity and cytokine secretion PMID: 19528259

Show More

Hide All

Subcellular Location
Cell membrane; Single-pass type I membrane protein.
Tissue Specificity
Not detected in any normal tissue tested. Expressed at the surface of several tumor cell lines including T and B-lymphomas, myeloid leukemias, melanomas, carcinomas and large T SV40 antigen-transformed cells (at protein level).
Database Links

HGNC: 42400

OMIM: 613714

KEGG: hsa:374383

STRING: 9606.ENSP00000341637

UniGene: Hs.146274

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*